{"id":"NCT03564119","sponsor":"Sol-Gel Technologies, Ltd.","briefTitle":"A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea","officialTitle":"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-21","primaryCompletion":"2019-06-10","completion":"2019-06-10","firstPosted":"2018-06-20","resultsPosted":"2021-12-15","lastUpdate":"2021-12-15"},"enrollment":372,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Papulopustular Rosacea"],"interventions":[{"type":"DRUG","name":"S5G4T-1","otherNames":["Encapsulated benzoyl peroxide (E-BPO) cream"]},{"type":"DRUG","name":"S5G4T-2","otherNames":["Vehicle cream"]}],"arms":[{"label":"S5G4T-1","type":"EXPERIMENTAL"},{"label":"S5G4T-2 Vehicle Cream","type":"PLACEBO_COMPARATOR"}],"summary":"To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.","primaryOutcome":{"measure":"Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12","timeFrame":"Baseline through Week 12","effectByArm":[{"arm":"S5G4T-1","deltaMin":50.1,"sd":null},{"arm":"S5G4T-2 Vehicle Cream","deltaMin":25.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37636253"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":248},"commonTop":["Nasopharyngitis","Application site pain","Urinary tract infection","Influenza","Upper respiratory tract infection"]}}